Zynrelef Solution
NDC Package 47426-503-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Zynrelef (bupivacaine and meloxicam) solution is zYNRELEF is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty. This formulation utilizes a solution delivery system. Marketed by Heron Therapeutics, Inc., this product is identified by NDC 47426-503 and is authorized under FDA application NDA211988.

Identification & Billing

NDC Package Code
47426-503-01
Package Description
1 CARTON in 1 KIT / 1 VIAL, SINGLE-DOSE in 1 CARTON (47426-503-03) / 2.3 mL in 1 VIAL, SINGLE-DOSE
Product Code
47426-503
11-Digit Billing Format
47426050301
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2560306 - ZYNRELEF (BUPivacaine 200 MG / meloxicam 6 MG) in 7 ML Extended Release Solution
  • RxCUI: 2560306 - 7 ML bupivacaine 29.3 MG/ML / meloxicam 0.88 MG/ML Injection [Zynrelef]
  • RxCUI: 2560306 - Zynrelef (bupivacaine 200 MG / meloxicam 6 MG) per 7 ML Extended Release Solution
  • RxCUI: 2560308 - ZYNRELEF (BUPivacaine 400 MG / meloxicam 12 MG) in 14 ML Extended Release Solution
  • RxCUI: 2560308 - 14 ML bupivacaine 29.3 MG/ML / meloxicam 0.88 MG/ML Injection [Zynrelef]

Clinical Specifications

Proprietary Name
Zynrelef
Non-Proprietary Name
Bupivacaine And Meloxicam
Substance Name
Bupivacaine; Meloxicam
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Infiltration - Administration that results in substances passing into tissue spaces or into cells.
Active Ingredient(s)
Pharmacologic Class
Usage Information
ZYNRELEF is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Regulatory & Marketing

Labeler Name
Heron Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA211988
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-01-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0668
Source: OPPS
Instill, bupivac and meloxic
HCPCS Dosage 1 MG - 0.03 MG
Units / Pkg 200

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 47426-503-01 identifies a specific commercial package of 1 carton in 1 kit / 1 vial, single-dose in 1 carton (47426-503-03) / 2.3 ml in 1 vial, single-dose of Zynrelef, a human prescription drug labeled by Heron Therapeutics, Inc.. This solution is formulated for infiltration use and contains bupivacaine; meloxicam as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Heron Therapeutics, Inc. on December 01, 2024. The current certification is valid through December 31, 2027.

How is this Heron Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 47426050301. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
47426-503-01
11-Digit CMS (5-4-2)
47426-0503-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.